Search
simeprevir (Olysio, TMC435)
Indications:
- for use with pegylated interferon & ribovirin for treatment of hepatitis C virus genotype 1 in adults [1,2]
* potential to be repurposed as COVID-19 therapy [5]
Dosage:
- 150 mg PO daily
Capsule: 150 mg
Adverse effects:
- may exacerbate hepatitis B infection [3,4]
Mechanism of action:
- NS3/4A antiviral protease inhibitor
General
antiviral protease inhibitor
References
- Sax PE
HIV and ID Observations
Simeprevir and Sofosbuvir Submitted to FDA - Clock Ticking on
Boceprevir, Telaprevir, Even Interferon
cited in:
Physician's First Watch for April 11, 2013
Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
http://blogs.jwatch.org/hiv-id-observations/index.php/simeprevir-and-sofosbuvir-submitted-to-fda-clock-ticking-on-boceprevir-telaprevir-even-interferon/2013/04/10/?q=pfw-featured
- FDA News Release: Nov. 22, 2013
FDA approves new treatment for hepatitis C virus
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm
- Collins JM et al.
Hepatitis B virus reactivation during successful treatment of
hepatitis C virus with sofosbuvir and simeprevir.
Clin Infect Dis 2015 Oct 15; 61:1304.
PMID: 26082511
http://cid.oxfordjournals.org/content/61/8/1304
- Balagopal A and Thio CL.
Another call to cure hepatitis B.
Clin Infect Dis 2015 Oct 15; 61:1307
PMID: 26082512
http://cid.oxfordjournals.org/content/61/8/1307
- FDA Drug Safety Communication: Oct 4, 2016
FDA warns about the risk of hepatitis B reactivating in some
patients treated with direct-acting antivirals for hepatitis C.
http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
- The Scripps Research Institute
Extensive study identifies over a dozen existing drugs as potential
COVID-19 therapies.
MedicalXpress 2021. June 3
https://medicalxpress.com/news/2021-06-extensive-dozen-drugs-potential-covid-.html